Galapagos to build fibrosis pipeline via extended Fibrocor partnership

In a move that could refill its fibrosis pipeline, Galapagos expanded its year-old collaboration with Fibrocor, adding options to exclusively license four fibrosis programs.

Under the original deal, announced December 2018, Toronto-based Fibrocor

Read the full 337 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE